AR049410A1 - Procedimiento para la preparacion de una 4-(benzimidazolilmetilamino)-benzamidina - Google Patents

Procedimiento para la preparacion de una 4-(benzimidazolilmetilamino)-benzamidina

Info

Publication number
AR049410A1
AR049410A1 ARP050102596A ARP050102596A AR049410A1 AR 049410 A1 AR049410 A1 AR 049410A1 AR P050102596 A ARP050102596 A AR P050102596A AR P050102596 A ARP050102596 A AR P050102596A AR 049410 A1 AR049410 A1 AR 049410A1
Authority
AR
Argentina
Prior art keywords
benzamidine
preparation
benzimidazolilmetilamino
procedure
optionally substituted
Prior art date
Application number
ARP050102596A
Other languages
English (en)
Inventor
Georg Zerban
Kerstin Schlarb
Gunter Koch
Rainer Hamm
Arndt Hausherr
Heinz-Peter Schmitt
Bjoern Weyell
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34925482&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR049410(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR049410A1 publication Critical patent/AR049410A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C07D271/07—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles with oxygen, sulfur or nitrogen atoms, directly attached to ring carbon atoms, the nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)

Abstract

La presente se refiere a un procedimiento para la preparacion de una 4-benzimidazol-2-ilmetilamino)-benzamidina eventualmente sustituida, caracterizado porque: (a) un diaminobenceno eventualmente sustituido de forma correspondiente se condensa con ácido 2-[4-(1,2,4-oxadiazol-5-on-3-il)-fenilamino]-acético; (b) el producto así obtenido se hidrogena y (c) el grupo amidino eventualmene se carbonila.
ARP050102596A 2004-06-25 2005-06-24 Procedimiento para la preparacion de una 4-(benzimidazolilmetilamino)-benzamidina AR049410A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04014917A EP1609784A1 (de) 2004-06-25 2004-06-25 Verfahren zur Herstellung von 4-(Benzimidazolylmethylamino)-Benzamidinen

Publications (1)

Publication Number Publication Date
AR049410A1 true AR049410A1 (es) 2006-07-26

Family

ID=34925482

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050102596A AR049410A1 (es) 2004-06-25 2005-06-24 Procedimiento para la preparacion de una 4-(benzimidazolilmetilamino)-benzamidina

Country Status (20)

Country Link
US (2) US7202368B2 (es)
EP (2) EP1609784A1 (es)
JP (1) JP5073486B2 (es)
KR (1) KR101298507B1 (es)
CN (1) CN1972919B (es)
AR (1) AR049410A1 (es)
AU (1) AU2005256424B2 (es)
BR (1) BRPI0511318B8 (es)
CA (1) CA2570499C (es)
DK (1) DK1761510T3 (es)
ES (1) ES2543982T3 (es)
HU (1) HUE027198T2 (es)
IL (2) IL180247A (es)
MX (1) MXPA06015210A (es)
NZ (1) NZ552809A (es)
PL (1) PL1761510T3 (es)
RU (1) RU2401264C2 (es)
TW (1) TWI364417B (es)
WO (1) WO2006000353A1 (es)
ZA (1) ZA200609918B (es)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030181488A1 (en) * 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
DE10339862A1 (de) * 2003-08-29 2005-03-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel
DE102005020002A1 (de) * 2005-04-27 2006-11-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Physiologisch verträgliche Salze von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester
DE102005061623A1 (de) * 2005-12-21 2007-06-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verbessertes Verfahren zur Herstellung von 4-(Benzimidazolylmethylamino)-Benzamidinen und deren Salzen
DE102005061624A1 (de) 2005-12-21 2007-06-28 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verbessertes Verfahren zur Herstellung von Salzen von 4-(Benzimidazolylmethylamino)-Benzamidinen
WO2008043759A1 (en) * 2006-10-10 2008-04-17 Boehringer Ingelheim International Gmbh Physiologically acceptable salts of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester
DE102006054005A1 (de) * 2006-11-16 2008-05-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Polymorphe von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester
EP1956018A1 (de) * 2007-02-06 2008-08-13 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Herstellung eines Benzimidazolderivats
CZ305085B6 (cs) * 2008-03-14 2015-04-29 Zentiva, K.S. Způsob přípravy dabigatranu
AU2009228795B2 (en) * 2008-03-28 2014-02-13 Boehringer Ingelheim International Gmbh Process for preparing orally administered dabigatran formulations
DK2297132T3 (da) * 2008-06-16 2015-05-26 Boehringer Ingelheim Int Fremgangsmåde til fremstilling af et mellemprodukt af dabigatran-etexilat
TWI436994B (zh) 2008-07-14 2014-05-11 Boehringer Ingelheim Int 製備含有達比加群（ｄａｂｉｇａｔｒａｎ）之藥物組合物的新穎方法
CZ2008669A3 (cs) * 2008-10-24 2010-05-05 Zentiva, A. S. Zpusob prípravy dabigatranu a jeho meziprodukty
CN102050815B (zh) * 2009-11-06 2014-04-02 北京美倍他药物研究有限公司 作为前药的达比加群的酯衍生物
CN102050814B (zh) * 2009-11-06 2014-05-28 北京美倍他药物研究有限公司 达比加群的酯衍生物
US8399678B2 (en) * 2009-11-18 2013-03-19 Boehringer Ingelheim International Gmbh Process for the manufacture of dabigatran etexilate
EP2937343A1 (en) 2010-07-09 2015-10-28 Esteve Química, S.A. Process of preparing a thrombin specific inhibitor
WO2012004397A1 (en) 2010-07-09 2012-01-12 Esteve Química, S.A. Intermediates and process for preparing a thrombin specific inhibitor
PL2603503T3 (pl) 2010-09-27 2015-12-31 Ratiopharm Gmbh Sól bismesylanowa eteksylanu dabigatranu, postacie stałe i sposób ich otrzymywania
WO2012077136A2 (en) * 2010-12-06 2012-06-14 Msn Laboratories Limited Process for the preparation of benzimidazole derivatives and its salts
EP2522662A1 (en) 2011-05-11 2012-11-14 Medichem, S.A. Dabigatran etexilate and related substances, processes and compositions, and use of the substances as reference standards and markers
HUP1100244A2 (hu) 2011-05-11 2012-11-28 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Gyógyszeripari intermedierek és eljárás elõállításukra
US9212166B2 (en) 2012-01-20 2015-12-15 Cadila Healthcare Limited Process for the preparation of dabigatran etexilate mesylate and polymorphs of intermediates thereof
WO2013150545A2 (en) 2012-04-02 2013-10-10 Msn Laboratories Limited Process for the preparation of benzimidazole derivatives and salts thereof
WO2014020555A2 (en) * 2012-08-01 2014-02-06 Alembic Pharmaceuticals Limited An improved process for the preparation of dabigatran etexilate mesylate
WO2014049585A2 (en) * 2012-09-28 2014-04-03 Ranbaxy Laboratories Limited Process for the preparation of dabigatran etexilate or pharmaceutically acceptable salt thereof
US9399616B2 (en) 2012-10-22 2016-07-26 Boehringer Ingelheim International Gmbh Process for the manufacture of 4-aminobenzoamidine dihydrochloride
WO2014068587A2 (en) * 2012-10-29 2014-05-08 Biophore India Pharmaceuticals Pvt. Ltd. An improved process for the synthesis of dabigatran and its intermediates
US10077251B2 (en) 2012-10-29 2018-09-18 Biophore India Pharmaceuticals Pvt. Ltd. Process for the synthesis of Dabigatran Etexilate and its intermediates
WO2014178017A1 (en) * 2013-04-30 2014-11-06 Ranbaxy Laboratories Limited Dabigatran etexilate impurity, process of its preparation, and its use as a reference standard
EP2835370A1 (en) 2013-08-08 2015-02-11 Medichem, S.A. New crystals of dabigatran etexilate mesylate
CN103626740B (zh) * 2013-12-05 2015-02-04 南京欧信医药技术有限公司 一种化合物的合成方法
CN103772358A (zh) * 2014-01-07 2014-05-07 万特制药(海南)有限公司 一种制备达比加群酯的合成方法
WO2015128875A2 (en) 2014-02-26 2015-09-03 Megafine Pharma (P) Ltd. A process for preparation of dabigatran etexilate mesylate and intermediates thereof
CN105461686A (zh) * 2014-08-25 2016-04-06 江苏豪森药业股份有限公司 制备高纯度甲磺酸达比加群酯晶型的方法
CN104910047B (zh) * 2015-05-11 2017-06-06 常州市阳光药业有限公司 达比加群酯中间体的制备方法
US20210280944A1 (en) 2018-10-29 2021-09-09 Lg Chem, Ltd. Separator for electrochemical device and method for manufacturing the same
EP3771465A1 (en) 2019-08-01 2021-02-03 Zaklady Farmaceutyczne Polpharma SA Pharmaceutical composition comprising dabigatran etexilate
CN116354952A (zh) * 2023-01-06 2023-06-30 宿迁盛基医药科技有限公司 一种达比加群酯关键中间体的合成工艺

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19516483A1 (de) 1995-05-05 1996-11-07 Merck Patent Gmbh Adhäsionsrezeptor-Antagonisten
PE121699A1 (es) * 1997-02-18 1999-12-08 Boehringer Ingelheim Pharma Heterociclos biciclicos disustituidos como inhibidores de la trombina
US6414008B1 (en) * 1997-04-29 2002-07-02 Boehringer Ingelheim Pharma Kg Disubstituted bicyclic heterocycles, the preparation thereof, and their use as pharmaceutical compositions
TWI248435B (en) 1998-07-04 2006-02-01 Boehringer Ingelheim Pharma Benzimidazoles, the preparation thereof and their use as pharmaceutical compositions
US6248770B1 (en) * 1998-07-09 2001-06-19 Boehringer Ingelheim Pharma Kg Benzimidazoles having antithrombotic activity
DE19962329A1 (de) * 1999-12-23 2001-06-28 Boehringer Ingelheim Pharma Benzimidazole, deren Herstellung und deren Verwendung als Arzneimittel
US6451832B2 (en) * 1999-12-23 2002-09-17 Boehringer Ingelheim Pharma Kg Benzimidazoles with antithrombotic activity
EP1574516A1 (en) * 2004-03-05 2005-09-14 Sanofi-Aventis Antithrombotic compound

Also Published As

Publication number Publication date
HUE027198T2 (en) 2016-08-29
US20070149589A1 (en) 2007-06-28
EP1761510A1 (de) 2007-03-14
RU2401264C2 (ru) 2010-10-10
DK1761510T3 (en) 2015-08-17
US20060004064A1 (en) 2006-01-05
PL1761510T3 (pl) 2015-10-30
BRPI0511318B1 (pt) 2018-02-14
IL180247A (en) 2011-11-30
IL180247A0 (en) 2007-07-04
CA2570499C (en) 2013-08-06
NZ552809A (en) 2009-06-26
AU2005256424A1 (en) 2006-01-05
ES2543982T3 (es) 2015-08-26
BRPI0511318A (pt) 2007-12-04
CA2570499A1 (en) 2006-01-05
JP2008503519A (ja) 2008-02-07
IL211491A0 (en) 2011-05-31
WO2006000353A1 (de) 2006-01-05
EP1761510B1 (de) 2015-05-13
EP1609784A1 (de) 2005-12-28
KR101298507B1 (ko) 2013-08-22
TW200613287A (en) 2006-05-01
US7202368B2 (en) 2007-04-10
KR20070029817A (ko) 2007-03-14
US7459566B2 (en) 2008-12-02
BRPI0511318B8 (pt) 2021-05-25
IL211491A (en) 2012-05-31
AU2005256424B2 (en) 2011-12-08
TWI364417B (en) 2012-05-21
CN1972919A (zh) 2007-05-30
JP5073486B2 (ja) 2012-11-14
CN1972919B (zh) 2012-06-27
RU2007102631A (ru) 2008-07-27
ZA200609918B (en) 2008-10-29
MXPA06015210A (es) 2007-03-15

Similar Documents

Publication Publication Date Title
AR049410A1 (es) Procedimiento para la preparacion de una 4-(benzimidazolilmetilamino)-benzamidina
AR058571A1 (es) Procedimiento mejorado para la preparacion de sales de 4-(bencimidazolilmetilamino)-benzamidinas
ECSP077984A (es) Formulacion de un inhibidor de agregacion de plaquetas de tienopiridina
TR201821186T4 (tr) Uzun süre etkili büyüme hormonu ve bunun üretim metotları.
WO2008082508A3 (en) Process for the preparation of 6,6-dimethyl-3-azabicyclo- [3.1.0]- hexane compounds utilizing bisulfite intermediate
WO2008083294A3 (en) Solar cell having active region with nanostructures having energy wells
EA201171216A1 (ru) Фенилацетат l-орнитина и способы его получения
EA200500239A1 (ru) Новый способ синтеза (1s)-4-,5-диметокси-1-(метиламинометил)-бензоциклобутана и его солей присоединения и применение при синтезе ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой
FR2937323B1 (fr) Procede de preparation d'un materiau composite thermoplastique a base de nanotubes, notamment de carbone
NO20075555L (no) Fremgangsmate for fremstilling av fosfolipider
GT200500354A (es) Metodo para preparar n-fenilpirazol-1-carboxamidas
BRPI0515649A (pt) processo para preparação de composições de anticorpos altamente concentradas e processo para concentrar proteìnas
MX2008014101A (es) Acidos carboxilicos sustituidos con 4,5-difenil-pirimidinilamino, metodo para su produccion y su uso como medicamentos.
BR112013010456A2 (pt) método para controlar um conversor tipo dc/dc ressonante em série
PE20141151A1 (es) Proteinas de union al antigeno cd27l
WO2009083225A3 (en) Antibody-containing formulation for the use for treating cardiovascular diseases associated with atherosclerosis
ME00814B (me) NOVI POSTUPAK SINTEZE 7,8-DIMETOKSI-1 ,3-DIHIDR0-2H-3-BENZAZEPIN-2-ON-a l PRIMENA U SINTEZI IVABRADINA l NJEGOVIH ADICIONIH SOLI SA FARMACEUTSKI PRIHVATLJIVOM KISELINOM
EP1930377A3 (de) Verfahren zur Herstellung von substituierten Aminoanthrachinonen
EA200701592A1 (ru) Композиты и способы их получения и использования
AR081593A1 (es) Procedimiento de sintesis de la ferroquina por aminacion reductora convergente
WO2009107971A3 (ko) 포스파티딜세린과 특이적으로 결합하는 폴리펩티드 및 이의 용도
FR2922810B1 (fr) Procede d'etirage d'un film en matiere synthetique se presentant sous la forme d'une bande allongee.
AR073640A1 (es) Metodo para obtener un drivado aminoindan mesilato
ECSP12012207A (es) Procedimiento para la preparación de 2-(ciclohexilmetil)-n-{2-[(2s)-1-metilpirrolidin-2-il]etil}-1,2,3,4-tetrahidroisoquinolin-7-sulfonamida
DK1871737T3 (da) Fremgangsmåde til fremstilling af aceteddikesyrearylamider

Legal Events

Date Code Title Description
FG Grant, registration